# How to choose an online GLP-1 program Canonical page: https://bodienvi.com/blog/how-to-choose-online-glp1-program Published September 22, 2026. Updated September 22, 2026. By Bodi Envi Clinical Content Team. How to judge a program rather than a price: the provider model, support after delivery, the price structure and the cancellation terms. ## A program is a relationship, not a purchase The guides on this site to choosing a personalized compounded semaglutide or tirzepatide provider are about legitimacy: is there a licensed prescriber, a state-licensed pharmacy, a LegitScript listing, a published price and published terms. Those checks come first and this guide assumes they are passed. What it adds is the question of how a program actually works over the months the labels describe treatment lasting: who reviews you and how, what happens after the medication arrives, how the price is built, and how you leave. Those are the things that separate programs that pass the legitimacy checks from each other, and they can be read from a program's own published pages. This guide names no programs; Bodi Envi appears at the end as one labelled example. This is general information and not medical advice. Personalized Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to the approved products. A licensed provider decides whether treatment is appropriate for you. ## The provider model Every legitimate program has a licensed provider somewhere in it. The differences are in how that provider is involved. The questions to ask, and to answer from published pages: which clinical organization do the providers belong to, and is it named? Does a licensed provider review your full assessment before any prescription, or is the review a formality attached to a purchase? Does the same care team follow you after the prescription, and is that team reachable? And does the program say in writing that completing the assessment, or paying, does not guarantee a prescription? The last question is a useful test. The FDA's statement on unapproved GLP-1 drugs lists a seller that does not require screening and a prescription by a licensed doctor among its warning signs, and a program that promises medication before a provider has reviewed anything has told you how much the review weighs. The labels also assume a real review: both the Wegovy® and Zepbound® labels open with contraindications and warnings a prescriber is expected to weigh, from a family history of medullary thyroid carcinoma to current use of insulin or a sulfonylurea, and an assessment that does not ask about them is not one a provider could decide from. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What happens after the medication arrives The labels describe treatment as something a provider manages over time, not a single decision. The Wegovy® label lets a provider delay a dose increase by four weeks if a dose is not tolerated, and the Zepbound® label says to consider a lower maintenance dose if one is not tolerated. Both ask patients to report persistent nausea, vomiting or diarrhea promptly because of the risk of dehydration and kidney injury, and both direct that the medication be stopped if pancreatitis is suspected. Every one of those requires a way to reach a clinician after the vial is in your refrigerator. So ask: how do I contact my care team, is it a clinician or a support desk, and is it part of the program or an add-on? The FDA's statement lists a seller with no licensed doctor available to answer questions after you receive the medication among its warning signs, and it advises patients to contact the compounder or the telehealth platform with questions about instructions for use. A program built around the labels' expectations has a messaging channel to the care team, and says so. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## How pricing is structured The FDA's BeSafeRx page lists prices that seem too good to be true among its warning signs, and LegitScript's standards require offers to be accurate, transparent and not misleading. Beyond those, the structure of a price tells you how a program expects treatment to go. Published before payment. A price that appears only after you have entered card details is a warning in itself. Inclusive or itemized. Some prices cover a program: assessment, provider review, messaging and the medication when prescribed. Some cover a consultation with medication billed separately, or medication with the consultation extra. Neither is wrong, but a comparison between them is meaningless until both are itemized the same way. Flat or stepped by dose. The labels describe dose escalation over months. A price that rises at each step is a different total from one that stays flat, and it also changes who has a stake in the dose decision. A program that publishes a flat price has said that the decision to escalate carries no financial consequence for the patient. Monthly or prepaid. A prepaid term is a commitment, and its value depends entirely on the cancellation terms. Conditional on a prescription. What happens to your payment if the provider decides not to prescribe should be published, since the program itself should be saying that outcome is possible. ## What the cancellation terms say A program's refund and cancellation policy is the document most worth reading before choosing a plan and least often read. What it should contain: how to cancel, in what form, and within what window; what is refunded at each stage, before review, after review, after a prescription, after dispensing; what happens to medication already dispensed, which for a compounded product made for one patient is usually not returnable; and who to contact about a problem with the medication itself, which is typically the dispensing pharmacy. LegitScript's requirement that offers be transparent is the standard; the policy is the evidence. A program that summarizes its terms in a sentence on the pricing page but does not publish the policy has not met it. One that publishes a policy you can read, even a strict one, has. ## Questions to ask a program The four readings become a short list of questions, each answerable from a program's own pages. Which clinical organization are the providers part of, and does a licensed provider review my full assessment before any prescription? Does the program say that completing the assessment does not guarantee a prescription? How do I reach my care team after the medication arrives, and is that a clinician? Is the price published before I pay, what does it include, and does it change with dose? What happens to my payment if the provider does not prescribe? Where is the refund and cancellation policy, and what does it say about a prepaid plan and about dispensed medication? A program that answers all of those in writing has passed the four readings; one that leaves any to a phone call has not. ## Putting it together Choosing a program, then, is four readings of its published pages after the legitimacy checks are passed: the provider model, the after-delivery support, the price structure and the cancellation terms. None of them is a matter of opinion, and none requires a phone call. A program that answers all four in writing has done what the FDA and LegitScript describe, and a program that leaves any of them to be discovered later has told you something too. ## Bodi Envi as one labeled example Read against those four, Bodi Envi's published statements are these. On the provider model: it is a LegitScript-certified U.S. telehealth platform and not a medical practice, pharmacy or medication manufacturer; clinical services for applicable programs are provided by Wasef Health, PC, whose licensed physicians and nurse practitioners independently review patient information and make all clinical decisions; and completing an assessment or paying for a program does not guarantee a prescription. On after-delivery support: eligible patients can communicate with their care team through the patient portal according to their program, and treatment plans and doses may be adjusted only through clinical evaluation and provider judgment. On pricing: published on the Plans page, personalized compounded semaglutide from $155 to $125 per month and personalized compounded tirzepatide from $229 to $175 per month depending on term, the same at every dose since pricing does not increase based solely on dosage strength, including the assessment, provider review, care team messaging, a GLP-1 ebook and diet plan, and the medication when prescribed. On cancellation: governed by the published cancellation policy, which accepts a request through the patient portal or by email to info@bodienvi.com before the provider review and prescription, and states that dispensed medications are non-refundable once an order has been processed or shipped, with no partial refunds on 3, 6 or 12 month plans. Those are Bodi Envi's own statements, given as an example of the four readings answered in writing and not as a comparison with anyone. Apply the same readings to any program, this one included. Personalized Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to the approved products; the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. This guide is general information and not medical advice, and a licensed provider decides whether treatment is appropriate for you. ## Frequently asked questions ### What is the difference between choosing a provider and choosing a program? A provider check asks whether a prescriber, a pharmacy and a platform are legitimate, using the FDA's and LegitScript's published standards. A program check asks how the whole arrangement works over months: who reviews you and how, what support exists after the medication arrives, how the price is built, and how you leave. This guide is about the second. ### What should I ask about the provider model? Which clinical organization the providers belong to, whether a licensed provider reviews your full assessment before any prescription, whether the same team follows you afterwards, and whether the platform says in writing that completing the assessment does not guarantee a prescription. The FDA's warning signs include no screening by a licensed doctor and no doctor available afterwards. ### Why does messaging after delivery matter? Because the labels expect a provider to respond during treatment: to slow an escalation or lower a dose when one is not tolerated, and to be told promptly about persistent nausea, vomiting or diarrhea. The FDA's GLP-1 statement lists a seller with no licensed doctor available after you receive the medication among its warning signs. ### How should pricing be structured? It should be published before you pay, say what it includes, say whether it changes with dose, and say what happens if the provider does not prescribe. A monthly price and a prepaid price for several months are different commitments, and the refund policy is where the difference lives. ### What should the cancellation terms say? How to cancel, in what form and within what window, what is refunded at each stage, and what happens to medication already dispensed. LegitScript's standards require offers to be transparent and not misleading; a program that meets them publishes these terms where you can read them before choosing a plan. ### How does Bodi Envi's program read against this? Bodi Envi publishes a provider model through Wasef Health, PC with a licensed provider deciding, ongoing care team messaging through the patient portal, pricing on the Plans page that is the same at every dose and includes the medication when prescribed, and a refund policy that sets a written request window after the provider review and states that dispensed medication is non-refundable. ## Sources - FDA, BeSafeRx, Considering an Online Pharmacy?: https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy (checked September 2026) - FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, dated September 1, 2026: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (checked September 2026) - LegitScript, Healthcare Certification: https://www.legitscript.com/certification/healthcare-certification/ (checked September 2026) - Wegovy® (semaglutide) injection prescribing information, DailyMed, revised June 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (checked September 2026) - Zepbound® (tirzepatide) injection prescribing information, DailyMed, revised August 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (checked September 2026) - Bodi Envi plans and pricing: https://bodienvi.com/plans (checked September 2026) - Bodi Envi refund policy: https://bodienvi.com/refund-policy (checked September 2026) - Bodi Envi, machine readable summary of programs and relationships: https://bodienvi.com/llms.txt (checked September 2026)